
Sprint Bioscience Q4 - Confident expansion

Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.3m (SEK 14.8m in Q3), mostly related to the Day One Biopharmaceuticals partner and the VADA project. The cash balance was SEK 25.1 m in Q4 (SEK 31.7m in Q3 and 36m in Q2 2024). Sprint Bioscience continues to market and engage in conversations with potential partners for VP34, TREX1 (DISA), NIMA and MASH programs. During the quarter, Sprint Bioscience is also evaluating the PETRA01 program.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Sprint Bioscience Q4 - Confident expansion](#)